Patents by Inventor Robert E. Garfield

Robert E. Garfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5948762
    Abstract: Dysmenorrhea, disfunctional uterine bleeding, preterm labor and postpartum labor in female mammals are treated by inhibiting uterine contractility by administering thereto a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in combination with one or more of a prostaglandin inhibitor, a prostacyclin-mimetic, a progestin, an oxytocin antagonist or a .beta.-agonist in an amount effective to ameliorate the symptoms thereof; and inadequate menses treated and induction of abortion or stimulation of labor in a pregnant female is achieved by uterine contractility stimulation by administering thereto a nitric oxide inhibitor, either alone or optionally in a combination of progesterone antagonist, an oxytocin or-oxytocin analogue antagonist or a prostaglandin.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: September 7, 1999
    Assignees: Schering Aktiengesellschaft, The University of Texas System
    Inventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampalli
  • Patent number: 5906987
    Abstract: The symptoms of climacterium in male mammals, e.g., hypertension, cardiovascular disease and osteoporosis, are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, in combination with an androgen, an aromatase inhibitor or both, wherein the circulating levels of testosterone in the afflicted individual are increased.
    Type: Grant
    Filed: March 10, 1997
    Date of Patent: May 25, 1999
    Assignees: Schering Aktiengesellschaft and Board of Regents, The University of Texas System
    Inventors: Kristof Chwalisz, Robert E. Garfield
  • Patent number: 5895783
    Abstract: Preeclampsia and preterm labor in a pregnant female mammal are treated by administering thereto a combination of a progestin and a nitric oxide synthase substrate, a nitric oxide donor or both, optionally in further combination with one or more of a cyclooxygenase inhibitor, a PGI.sub.2 -mimetic, a thromboxane (TXA.sub.2) inhibitor, a compound possessing TXA.sub.2 -agonistic and TXA.sub.2 -inhibiting properties, a compound possessing TXA.sub.2 -antagonistic and PGI.sub.2 -memetic activities, and a TXA.sub.2 antagonist.
    Type: Grant
    Filed: July 16, 1993
    Date of Patent: April 20, 1999
    Assignees: Schering Aktiengesellschaft, The University of Texas
    Inventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampal Li
  • Patent number: 5811416
    Abstract: A pharmaceutical composition for and methods of treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal, treatment of atherosclerotic vascular disease and hypertension in males as well as females, and for hormone replacement therapy in peri- and post-menopausal females, comprising administering effective amounts of an endothelin antagonist and/or an endothelin synthase inhibitor or both, in combination witha progestin, and/or an estrogen, and/ora cyclooxygenase inhibitor, and/ora nitric oxide donor and/or nitric oxide substrate,to prevent and/or ameliorate said conditions, are disclosed. In the method aspects, the endothelin antagonist and/or endothelin synthase inhibitor can be administered alone for treatment of menstrual disorders, e.g., dysmenorrhea, in a non-pregnant female, preterm labor, preeclampsia and/or fetal growth retardation in a pregnant female mammal.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: September 22, 1998
    Assignees: Board of Regents The University of Texas System, Schering Aktiengesellschaft
    Inventors: Kristof Chwalisz, Robert E. Garfield
  • Patent number: 5789442
    Abstract: The invention provides a method for the treatment and prevention of urinary incontinence in mammals, e.g., human males and females, especially nonpregnant female mammals, by administering a nitric oxide synthase substrate and/or nitric oxide donor, alone or in combination with an estrogenic agent and/or a progestational substance, with or without supplementation with an alpha-adrenergic agonist, beta-adrenergic receptor blocking agent, cholinergic-receptor blocking compound or a cholinergic-receptor-stimulating drug, as well as pharmaceutical compositions useful in practicing the methods of this invention.
    Type: Grant
    Filed: January 18, 1996
    Date of Patent: August 4, 1998
    Assignee: Schering Aktiengesellschaft
    Inventors: Robert E. Garfield, Kristof Chwalisz
  • Patent number: 5776073
    Abstract: A method and apparatus is presented for recording uterine electrical activity from the surface of the abdomen or vagina for the purpose of diagnosing contractile patterns of the uterus or abdominal muscles in pregnant and nonpregnant patients. The present invention provides data analysis techniques for analyzing electromyographic data measured from the surface of a patient to characterize uterine activity. The method and apparatus described include algorithms for the systematic analysis of electrical signals recorded from the abdominal surface. Such processing comprises integration of signals, frequency spectral analysis, 3-dimensional power density mesh plots, vector analysis, fast wavelet transform, and joint time-frequency characteristics. These techniques and apparatus are appropriate for use in a clinic or through communication lines for use as a remote or home uterine monitoring system.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: July 7, 1998
    Assignee: Board of Regents, University of Texas System
    Inventors: Robert E. Garfield, Mary B. Boyle
  • Patent number: 5721278
    Abstract: Inhibition of ovulation in a female may be achieved by administering a nitric oxide synthase inhibitor, alone or in combination with one or more of a progestin, an estrogen, and an LH-RH antagonist, thereby preventing conception. The stimulation of ovulation in a female may be achieved by administering a nitric oxide source, optionally in further combination with one or more of clomiphene, a gonadotropin, and an LH-RH agonist.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 24, 1998
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert E. Garfield, Chandrasekhar Yallampalli
  • Patent number: 5698738
    Abstract: Nitric oxide has proved to mediate many important physiological processes. The nitric oxide donors of the present invention have a NONOate anion linked to an ortho-substituted aryl, a heteroaromatic substituent, asteroid, or a catecholamine. Preferred ortho substituents are alkoxy, halo, and alkyl. The cation of the salt is an alkali metal, an alkaline-earth metal, an ammonium or substituted ammonium group. Nitric oxide donors provided herein are more stable than that of nitrogen-bonded NONOates described previously. The by product left after release of NO, and the nitric oxide donors themselves, are very probably less carcinogenic than the corresponding nitrogen-bonded NONOates.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: December 16, 1997
    Assignees: Board of Regents, The University of Texas System, The Texas A&M University System
    Inventors: Robert E. Garfield, Alexandru T. Balaban, William A. Seitz, Douglas J. Klein, Melanie Lesko
  • Patent number: 5643944
    Abstract: The stimulation of ovulation in a female may be achieved by administering a nitric oxide source, optionally in further combination with one or more of clomiphene, a gonadotropin, and an LH-RH agonist.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 1, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Robert E. Garfield, Chandrasekhar Yallampalli
  • Patent number: 5623939
    Abstract: A method and apparatus is presented for recording uterine electrical activity from the surface of the abdomen or vagina for the purpose of diagnosing contractile patterns of the uterus in pregnant and nonpregnant patients. The present invention provides data analysis techniques for analyzing electromyographic data measured from the surface of a patient to characterize uterine activity. The method and apparatus described include algorithms for the systematic analysis of electrical signals recorded from the abdominal surface. Such processing comprises integration of signals, frequency spectral analysis, 3-dimensional power density mesh plots, vector analysis, fast wavelet transform, and joint time-frequency characteristics. These techniques and apparatus are appropriate for use in a clinic or through communication lines for use as a remote or home uterine monitoring system.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: April 29, 1997
    Assignee: Board of Regents, University of Texas System
    Inventor: Robert E. Garfield
  • Patent number: 5595970
    Abstract: The symptoms of the climacterium are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, alone or optionally in combination with a progestin or, in the case of a non-pregnant female, either a progestin or an estrogen or both.
    Type: Grant
    Filed: November 16, 1993
    Date of Patent: January 21, 1997
    Assignee: Schering Aktiengesellschaft
    Inventors: Robert E. Garfield, Krzysztof Chwalisz, Radoslaw Bukowski, Chandra Yallampalli
  • Patent number: 5546953
    Abstract: A method and apparatus for recording and analyzing uterine electrical and mechanical activity from the abdominal surface. Electrodes are applied to the abdominal surface of a patient, and electromyographic signals produced by the electrodes are digitized, stored and analyzed to assess uterine electrical activity. Assessment of the function of other smooth muscle organs, for example the bladder and lower gastrointestinal tract is also contemplated.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: August 20, 1996
    Assignee: Board of Regents, The University of Texas System
    Inventor: Robert E. Garfield
  • Patent number: 5470847
    Abstract: Inhibition of ovulation in a female may be achieved by administering an arginine derivative which acts as a nitric oxide sythase inhibitor, alone or in combination with one or more of a progestin, an estrogen, and an LH-RH antagonist, thereby preventing conception.
    Type: Grant
    Filed: December 10, 1993
    Date of Patent: November 28, 1995
    Assignee: Board of Regents, the University of Texas System
    Inventors: Robert E. Garfield, Chandrasekhar Yallampalli